Early identification of an underlying genetic cause can help inform appropriate care for children with developmental delay, autism spectrum disorders, and congenital anomalies.
Quest offers the following tests
Chromosomal microarray analysis (CMA), a guideline-supported, first-line genetic test that uses advanced array technology to detect clinically significant chromosomal changes. With strong technical performance and one of the fastest turnaround times available, CMA can help clinicians move more quickly from evaluation to informed next steps.
Whole exome sequencing (WES), which provides a broader genetic assessment across thousands of genes and can help identify an underlying cause in neurodevelopmental conditions, congenital anomalies, complex presentations, or inconclusive previous genetic testing.
